9 unchanged sentences
patent application directed to CRISPR/Cas9 that are co-owned by the Broad Institute and the Massachusetts Institute of Technology (“MIT”), and in some cases Harvard (collectively referred to as “Broad”), and in-licensed by us were involved in a first interference with a U.S.
−Removed: patent application that is co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively referred to “CVC”).
−Removed: An interference is a proceeding in USPTO before the Patent Trial and Appeal Board of the USPTO (“PTAB”) to determine priority of invention of the subject matter of patent claims filed by different parties.
+Added: patent application that is co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively referred to as “CVC”).
+Added: An interference is a proceeding in the USPTO before the Patent Trial and Appeal Board of the USPTO (“PTAB”) to determine priority of invention of the subject matter of patent claims filed by different parties.
In this first interference, the PTAB made a judgment of no interference-in-fact in favor of the Broad, which was upheld on appeal.
18 unchanged sentences
the PTAB reaffirmed its previous decision favoring Broad.
−Removed: CVC retains the right to appeal the PTAB’s decision to the CAFC.
−Removed: It is uncertain if CVC will appeal and, if appealed, when or in what manner the CAFC will act on any such appeal.
+Added: This decision by the PTAB has been appealed by CVC.
+Added: It is uncertain when or in what manner the CAFC will act on this appeal.
On December 14, 2020, the PTAB declared two new interferences involving a pending U.S.
60 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.